Xenex Makes De Novo Petition to FDA for LightStrike UV Room Disinfection Technology

SAN ANTONIO–(BUSINESS WIRE)–Xenex Disinfection Services, the world leader in UV disinfection technology for healthcare facilities, today announced it has filed a De Novo petition with the U.S. Food and Drug Administration (“FDA”) for medical device market authorization of its LightStrike+ ultraviolet (UV) room disinfection technology. The company’s patented device uses a xenon lamp to create broad spectrum UV light intended to quickly destroy pathogens on surfaces in healthcare facilities.